Hepatitis Therapeutics Market Statistics - 2030
The global hepatitis therapeutics market size was valued at $14,480 Million in 2020 and is projected to reach $19,716 Million by 2030 registering a CAGR of 3.1% from 2021 to 2030. Hepatitis is the inflammation of liver caused because of viral disease. Hepatitis is caused due to different infections known as infection A, infection B, infection C, infection D, infection E and infection G. The disease prompts irritation of liver tissues, which can trigger liver cirrhosis and malignant growth. The disease decreases liver capacity and harm to other body capacities. Hepatitis can be acute and chronic both. Among every one of the kinds, hepatitis B and C are the most hazardous and hard to treat.
The development of the hepatitis therapeutics market is driven by ascend in commonness of different hepatitis, expanding research and development work, clinical preliminaries of hepatitis drugs, expansion in number of item endorsements and product launches and development of novel hepatitis drugs in the treatment of different kinds of hepatitis. Increasing research coordinated efforts for the development of powerful medications in pipeline drives the market growth significantly. Besides, associations and joint effort in significant organizations ascend in persistent mindfulness in regards to hepatitis therapeutics treatment, and presentation of low-estimated hepatitis therapeutics is different variables that support the development of the market.
However, significant expense of hepatitis drugs is relied upon to limit the development of the hepatitis therapeutics market share. On the other hand, growing opportunities in emerging countries and sectors are anticipated to offer lucrative growth opportunities in the near future.
What is the Impact of COVID-19 Pandemic on the Hepatitis Therapeutics Market?
The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare.
There has also been a moderate effect on various healthcare services, including the hepatitis therapeutics market. The COVID-19 pandemic is an unpredicted worldwide general wellbeing challenge and is expected to adversely affect the hepatitis therapeutics market for the advancement of hepatitis drugs treatment to treat a wide range of hepatitis(s). During the COVID-19 pandemic from one side of the planet to the other, patients with hepatitis B have confronted various new difficulties in getting to clinical consideration and treatment because of deferred arrangements and de-prioritization of routine hepatitis or essential consideration administrations. Larger part of patients needed to change in accordance with telemedicine process, yet they additionally experienced trouble getting antiviral tops off and interruptions in mail-request conveyance of the medications. Some patients experienced issues when diagnosed with COVID-19 and with liver sickness at the same time.
Concerns were identified with the security and viability of COVID-19 antibodies for individuals living with hepatitis B and liver illness. In 2020, the COVID-19 pandemic disturbed the whole HCV benefits worldwide, with 25% fewer patients being started on treatment than in 2019. Hence, the overall impact of COVID-19 on hepatitis therapeutics market is positive, which will further drive the market growth.
Hepatitis Therapeutics Market Segmentation
The global hepatitis therapeutics market is segmented on the basis of disease type, drug class, distribution channel and region. On the basis of disease type, the market is further classified into hepatitis B, hepatitis C, and others (hepatitis A, D, E and G). By drug class, it is divided into oral antivirals, and immune modulators. Based on distribution channel, it is subdivided in to hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By Disease Type
Hepatitis C segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.
Segment Review
By disease type, the hepatitis C segment accounted for the largest share of the hepatitis therapeutics market in 2020. The large share of this segment can be attributed to the increasing prevalence of hepatitis C and rising product approvals by regulatory authorities.
Further, drug stores & retail pharmacies segment is anticipated to depict largest growth during the forecast period, due to increasing drug availability of both branded and generics. In addition, online providers are expected to witness fastest growth owing to the lucrative discount offers provided by the online providers, which is expected to attract more customers to opt for online provider’s services.
By Drug Class
Immune Modulators segment is projected as one of the most lucrative segment over the forecast period.
Snapshot of North America Genome Editing market
North America is projected to account for a major share of the global hepatitis therapeutics market during the forecast period. The market in the region is anticipated to witness growth in the future, owing to large patient population of hepatitis patients, huge availability of both branded and generic medications. And rising number of product approvals are propelling market growth in North America.
The key market players profiled in the report include Abbvie Inc., Bristol Myers & Squibb, Cipla Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Hoffmann-La Roche Ltd., Lupin Ltd., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., and Zydus Cadila.
By Region
Asia-Pacific region would exhibit the highest CAGR of 25.2 % during 2021-2030.
Key Benefits for Stakeholders
- The study provides an in-depth analysis of the global hepatitis therapeutics market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing hepatitis therapeutics market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products the market used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the hepatitis therapeutics market.
Hepatitis Therapeutics Market, by Disease Type Report Highlights
| Aspects | Details |
 By Disease Type |
|
 By Drug Class |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Gilead Sciences Inc., Cipla Inc., Lupin Ltd., Merck & Co. Inc., Zydus Cadila., Bristol Myers & Squibb, Abbvie Inc., Teva Pharmaceutical Industries Ltd., Hoffmann-La Roche Ltd., GlaxoSmithKline Plc. |
Analyst Review
Hepatitis therapeutics market growth includes rise in number of hepatitis patient population across the globe, rise in public awareness toward hepatitis and treatment and prevention methods has primarily driven the market growth over the past few years. Moreover, introduction of low-priced hepatitis therapeutic drugs are a major contributing factor for revenue generation in this market. Moreover, the market is witnessing intensified competition among the market players owing to the rising collaborations between major players. There has been an increased focus on the hepatitis therapeutics because of increased R&D activities and clinical trials on the drug candidates. Further, surge in hepatitis awareness and popularity of novel hepatitis therapeutics are expected to drive the growth of the market. On the contrary with market drivers, there are some major restraining factors such as high cost of hepatitis treatment therapy that limits the growth of the market. Furthermore, increase in demand of hepatitis therapeutics in emerging markets such as India, China, and Brazil is anticipated offer lucrative opportunities to the hepatitis therapeutics market over the forecast period.
Furthermore, hepatitis therapeutics market is dominated by North America due to the strong presence of the pharmaceuticals and biotechnology companies in the U.S. and is followed by Europe. The large share of North America can be attributed to factors such as the rising prevalence of hepatitis and its variants, and surge in research collaborations for the development of robust drugs pipeline, which are propelling the market growth in North America.
The total market value of Hepatitis Therapeutics market is $14,479.64 million in 2020.
The forcast period for Hepatitis Therapeutics market is 2021 to 2030
The market value of Hepatitis Therapeutics market in 2021 is $19,715.74 million.
The base year is 2020 in Hepatitis Therapeutics market
Top companies such as Abbvie Inc., Bristol Mayers & Squibb, Cipla Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Hoffmann-La Roche Ltd., Lupin Ltd., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., and Zydus Cadila held a high market position in 2020.
Based on drugs class, the CRISPR segment accounted for the largest share of the Hepatitis Therapeutics market in 2020. The large share of this segment can be attributed to the increasing demnad of the oral antivirals medications, rising products approvals and launches for treatment of hepatitis.
The growth of the hepatitis therapeutics market is driven by rise in prevalence of various hepatitis, increasing research and development, clinical trials of hepatitis drugs, increase in number of product approvals and product launch and surge in adoption of novel hepatitis drugs in the treatment of various types of hepatitis. However, high cost of hepatitis drugs is expected to restrain the growth of the hepatitis therapeutics market.
North America is projected to account for a major share of the global Hepatitis Therapeutics market during the forecast period. The market in the region is anticipated to grow in the future, owing to rising R&D activities in the U.S., large patient population of hepatitis patients, huge availability of both branded and generic medications. And rising number of product approvals are propelling market growth in North America.
Hepatitis Therapeutics refers to the medication that are used for the treatmet of hepatitis and its all variants. Oral antivirals and immune modulators are the two medications used to treat hepatitis.
The hepatitis therapeutics medications are used to treat all type of hepatitis that includes Hepatitis A, B, C, D and E.
Loading Table Of Content...
